SCHEMBL4135833

SCHEMBL4135833

CCOC(=O)c1cn2c3c(cc(SCCNC(=O)OC(C)(C)C)cc3c1=O)CC[C@H]2C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CYP1A2 P05177 1/20 0.42
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
ADRB2 P07550 1/20 0.38
HPGD P15428 3/20 0.34
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
LMNA P02545 2/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
ALDH1A1 P00352 3/20 0.33
TSHR P16473 1/20 0.33
MAPT P10636 1/20 0.32
THRB P10828 1/20 0.32
AKR1C3 P42330 1/20 0.32
AKR1C2 P52895 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4135830 1.00 KDM4E (0.42) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B
SCHEMBL4131578 0.87 KDM4E (0.46) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B
SCHEMBL4131576 0.87 KDM4E (0.46) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B
SCHEMBL4169500 0.85 KDM4E (0.49) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B
SCHEMBL13872059 0.84 KDM4E (0.41) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B
SCHEMBL5313782 0.84 KDM4E (0.51) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B
SCHEMBL4143472 0.84 KDM4E (0.51) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B
SCHEMBL4143470 0.84 KDM4E (0.51) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B
SCHEMBL4136265 0.83 KDM4E (0.42) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B
SCHEMBL4136260 0.83 KDM4E (0.42) KDM4ESMN1; SMN2CYP1A2PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090111760-A1 MACROLONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111760-A1 MACROLONE COMPOUNDS CYP51A1, MRPL21, MYD88 KDM4E 3897/4885SMN1; SMN2 2560/4885CYP1A2 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.